XGN Exagen Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: XGN

Price (delayed)

$1.4

Market cap

$24.13M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.34

Enterprise value

$10.87M

Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and ...

Highlights
The EPS has soared by 52% YoY and by 28% from the previous quarter
The company's net income has surged by 50% YoY and by 27% QoQ
XGN's quick ratio is down by 49% year-on-year and by 20% since the previous quarter
Exagen's equity has decreased by 47% YoY and by 17% from the previous quarter
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.exagen.com
Peers: PNTG OPCH MODV

Key stats

What are the main financial stats of XGN
Market
Shares outstanding
17.24M
Market cap
$24.13M
Enterprise value
$10.87M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.05
Price to sales (P/S)
0.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.21
Earnings
Revenue
$52.55M
EBIT
-$21.32M
EBITDA
-$18.21M
Free cash flow
-$15.27M
Per share
EPS
-$1.34
Free cash flow per share
-$0.86
Book value per share
$1.33
Revenue per share
$2.97
TBVPS
$3.22
Balance sheet
Total assets
$56.94M
Total liabilities
$34.25M
Debt
$23.23M
Equity
$22.69M
Working capital
$35.94M
Liquidity
Debt to equity
1.02
Current ratio
4.02
Quick ratio
3.62
Net debt/EBITDA
0.73
Margins
EBITDA margin
-34.7%
Gross margin
56.1%
Net margin
-45.1%
Operating margin
-43.5%
Efficiency
Return on assets
-36.3%
Return on equity
-80.3%
Return on invested capital
-47.6%
Return on capital employed
-47.3%
Return on sales
-40.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

XGN stock price

How has the Exagen stock price performed over time
Intraday
1.45%
1 week
-1.41%
1 month
-9.68%
1 year
-45.1%
YTD
-29.65%
QTD
-11.95%

Financial performance

How have Exagen's revenue and profit performed over time
Revenue
$52.55M
Gross profit
$29.46M
Operating income
-$22.84M
Net income
-$23.69M
Gross margin
56.1%
Net margin
-45.1%
The operating margin has soared by 57% YoY and by 30% from the previous quarter
XGN's net margin has soared by 57% year-on-year and by 28% since the previous quarter
The operating income has soared by 50% year-on-year and by 29% since the previous quarter
The company's net income has surged by 50% YoY and by 27% QoQ

Growth

What is Exagen's growth rate over time

Valuation

What is Exagen stock price valuation
P/E
N/A
P/B
1.05
P/S
0.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.21
The EPS has soared by 52% YoY and by 28% from the previous quarter
XGN's price to book (P/B) is 56% lower than its 5-year quarterly average of 2.4 and 25% lower than its last 4 quarters average of 1.4
Exagen's equity has decreased by 47% YoY and by 17% from the previous quarter
The P/S is 83% less than the 5-year quarterly average of 2.7 and 41% less than the last 4 quarters average of 0.8
Exagen's revenue has increased by 15% YoY

Efficiency

How efficient is Exagen business performance
The ROS has soared by 59% YoY and by 31% from the previous quarter
The company's return on invested capital rose by 48% YoY and by 23% QoQ
Exagen's return on assets has increased by 20% YoY and by 19% QoQ
The company's return on equity rose by 15% QoQ

Dividends

What is XGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for XGN.

Financial health

How did Exagen financials performed over time
The total assets is 66% greater than the total liabilities
XGN's quick ratio is down by 49% year-on-year and by 20% since the previous quarter
Exagen's current ratio has decreased by 47% YoY and by 17% from the previous quarter
XGN's debt is 2.4% greater than its equity
Exagen's equity has decreased by 47% YoY and by 17% from the previous quarter
XGN's debt is down by 33% year-on-year and by 4.1% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.